Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $437,316.25 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 15,211 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $28.75, for a total value of $437,316.25. Following the completion of the transaction, the chief accounting officer now owns 32,546 shares in the company, valued at $935,697.50. The trade was a 31.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals Stock Up 1.3%

KNSA traded up $0.40 on Friday, hitting $29.92. 516,835 shares of the company traded hands, compared to its average volume of 500,410. The company has a 50 day moving average of $24.10 and a 200-day moving average of $21.84. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $29.98. The stock has a market capitalization of $2.18 billion, a PE ratio of -213.73 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same period in the prior year, the business posted ($0.25) EPS. The business's revenue was up 72.5% on a year-over-year basis. On average, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Rhumbline Advisers boosted its stake in Kiniksa Pharmaceuticals by 6.4% during the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock valued at $1,393,000 after purchasing an additional 3,745 shares during the period. Strs Ohio bought a new position in Kiniksa Pharmaceuticals in the first quarter valued at about $595,000. Acadian Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after purchasing an additional 651,700 shares during the period. Fred Alger Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at about $485,000. Finally, Millennium Management LLC increased its position in shares of Kiniksa Pharmaceuticals by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KNSA shares. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.